About half of patients with asthma on tezepelumab had discontinued their daily maintenance oral corticosteroid doses by 52 ...

Data from the WAYFINDER study showed clinically meaningful reductions and discontinuations of oral corticosteroids.

Discover a study that found that tezepelumab also showed promise in patients previously unresponsive to other biologics.

The study evaluated 807 adults who initiated an anti–IL–5 therapy (79% mepolizumab, 21% benralizumab) between 2017 and 2020.

Results from the pivotal BATURA trial show that Airsupra (albuterol/budesonide) significantly outperformed albuterol ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...